English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

In patients with relapsing‐remitting multiple sclerosis (RRMS), interferon beta‐1b (IFNβ‐1b) reduces the occurrence of contrast enhancing lesions (CELs) on magnetic resonance imaging (MRI). Questions remain on the stability of IFNβ‐1b effect over time and its action beyond the reduction of CELs. In this study, we described the IFNβ‐1b effect by a mixed effects model, quantifying the interpatient variability associated with its parameters. Using a negative binomial distribution model as a natural history model, the effect of IFNβ‐1b was evaluated using different mathematical functions of time. IFNβ‐1b produced a decrease in the expected CEL numbers, inhibiting the formation of new CELs but did not promote the resolution of the already‐formed ones. Based on the final selected model, simulations were carried out to optimize the combined IFNβ‐1b‐corticosteroid therapy as a proof‐of‐concept. In summary, we provide evidence on the dynamics of CELs under IFNβ‐1b treatment that can be used to monitor the effects of therapies in MS.

A Population Approach to Characterize Interferon Beta‐1b Effect on Contrast Enhancing Lesions in Patients With Relapsing Remitting Multiple Sclerosis